Erythromycin salnacedin

Drug Profile

Erythromycin salnacedin

Alternative Names: Actagen; G 101

Latest Information Update: 09 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genta
  • Class Antiacnes; Antibacterials; Expectorants; Macrolides; Salicylates
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acne

Most Recent Events

  • 28 Aug 2001 Discontinued-III for Acne in France (Topical)
  • 28 Aug 2001 Discontinued-III for Acne in USA (Topical)
  • 21 Sep 1999 No-Development-Reported for Acne in France (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top